Despite operating in the popular women's health space, Repro Novo's CEO advises founders to pitch investors on tangible commercial opportunities and critical unmet needs. This focus on market gaps and pricing potential is more compelling than simply relying on a sector-specific trend for funding.

Related Insights

Treat your startup like a drug discovery experiment. A market's needs are like biological 'binding receptors'—they either exist or they don't. Marketing can raise awareness of your 'drug' (product), but it can't convince the body to grow new receptors. If you lack product-market fit, don't try to market your way out of it.

While VC pitches require an expansive vision, customer pitches are more effective when they're small and specific. After understanding their demand, describe your product narrowly as the exact tool that solves their immediate project. This precision builds confidence and creates pull.

Applying the "weird if it didn't work" framework to fundraising means shifting the narrative. Your goal is to construct a story where the market opportunity is so massive and your team's approach is so compelling that an investor's decision *not* to participate would feel like an obvious miss.

When evaluating a startup, don't accept analogous trends as proof of demand. For example, Drift's pitch deck used consumer messaging growth to justify B2B marketing software. A better approach is to find direct evidence of business users already struggling with the specific project the product addresses.

Investors like Stacy Brown-Philpot and Aileen Lee now expect founders to demonstrate a clear, rapid path to massive scale early on. The old assumption that the next funding round would solve for scalability is gone; proof is required upfront.

Instead of searching for a market to serve, founders should solve a problem they personally experience. This "bottom-up" approach guarantees product-market fit for at least one person—the founder—providing a solid foundation to build upon and avoiding the common failure of abstract, top-down market analysis.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

A core investment framework is to distinguish between 'pull' companies, where the market organically and virally demands the product, and 'push' companies that have to force their solution onto the market. The former indicates stronger product-market fit and a higher potential for efficient, scalable growth.

Using a child's toy analogy, demand is a pre-existing hole (e.g., a star shape) and your product is the block. Founders fail when they build a block and then search for a hole it fits. The real job is to first deeply understand the shape of the hole, then craft a block that fits it perfectly.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?